Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
1(13%)
Results Posted
29%(2 trials)

Phase Distribution

Ph phase_4
1
13%
Ph phase_1
1
13%
Ph not_applicable
4
50%
Ph phase_2
2
25%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 4Post-market surveillance
1(12.5%)
N/ANon-phased studies
4(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(7)

Detailed Status

Completed7
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (12.5%)
Phase 22 (25.0%)
Phase 41 (12.5%)
N/A4 (50.0%)

Trials by Status

recruiting113%
completed788%

Recent Activity

1 active trials
Showing 5 of 8
recruitingnot_applicable

Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.

NCT05578196
completedphase_2

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine

NCT02861586
completedphase_2

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

NCT04335136
completednot_applicable

Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients

NCT04063644
completednot_applicable

Hemiplegic Shoulder Pain and Rotator Cuff Injuries

NCT02465853
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05578196Not Applicable

Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.

Recruiting
NCT02861586Phase 2

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine

Completed
NCT04335136Phase 2

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

Completed
NCT04063644Not Applicable

Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients

Completed
NCT02465853Not Applicable

Hemiplegic Shoulder Pain and Rotator Cuff Injuries

Completed
NCT01747616Phase 1

Assessment of Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Subjects While Wearing Contact Lenses and Before Insertion of Contact Lenses

Completed
NCT00915070Not Applicable

Role of Endothelin-1 in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans

Completed
NCT00674713Phase 4

Effect of Acupuncture on Postoperative Nausea and Vomiting

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8